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Abstract
Background: HIV-infected and HIV-exposed, uninfected infants experience a high burden of infectious morbidity
and mortality. Hospitalization is an important metric for morbidity and is associated with high mortality, yet, little is
known about rates and causes of hospitalization among these infants in the first 12 months of life.
Methods: Using data from a prevention of mother-to-child transmission (PMTCT) trial (India SWEN), where HIV-
exposed breastfed infants were given extended nevirapine, we measured 12-month infant all-cause and cause-
specific hospitalization rates and hospitalization risk factors.
Results: Among 737 HIV-exposed Indian infants, 93 (13%) were HIV-infected, 15 (16%) were on HAART, and 260
(35%) were hospitalized 381 times by 12 months of life. Fifty-six percent of the hospitalizations were attributed to
infections; gastroenteritis was most common accounting for 31% of infectious hospitalizations. Gastrointestinal-
related hospitalizations steadily increased over time, peaking around 9 months. The 12-month all-cause
hospitalization, gastroenteritis-related hospitalization, and in-hospital mortality rates were 906/1000 PY, 229/1000 PY,
and 35/1000 PY respectively among HIV-infected infants and 497/1000 PY, 107/1000 PY, and 3/1000 PY respectively
among HIV-exposed, uninfected infants. Advanced maternal age, infant HIV infection, gestational age, and male sex
were associated with higher all-cause hospitalization risk while shorter duration of breastfeeding and abrupt
weaning were associated with gastroenteritis-related hospitalization.
Conclusions: HIV-exposed Indian infants experience high rates of all-cause and infectious hospitalization
(particularly gastroenteritis) and in-hospital mortality. HIV-infected infants are nearly 2-fold more likely to experience
hospitalization and 10-fold more likely to die compared to HIV-exposed, uninfected infants. The combination of
scaling up HIV PMTCT programs and implementing proven health measures against infections could significantly
reduce hospitalization morbidity and mortality among HIV-exposed Indian infants.
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Background
Pneumonia and gastroenteritis account for nearly 50% of
early childhood morbidity and mortality, particularly in
low-income country settings [1]. HIV-infection increases
the risks of these infections several fold and of mortality
approximately 9-fold in sub-Saharan Africa [2-5]. Some
studies have shown that HIV exposure, even in the
absence of infant HIV infection, also increases these
risks [6,7]. Most of these studies have defined morbidity
as infections, severe events, or grade 3 or 4 adverse
events using US NIH Division of AIDS toxicity scale;
few have used hospitalization as an outcome. Hospitali-
zation is an important measure of morbidity because it
provides discrete information about illness severity, may
be more comparable across studies than morbidity
events, and is associated with high mortality, particularly
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HAART [5].
India has the third highest number of HIV infections in
the world, with an estimated 21,000 newly HIV-infected
infants [8] and 180,000 HIV-exposed, uninfected infants
born each year [9,10]. Examining hospitalization morbid-
ity among HIV-infected and HIV-exposed, uninfected
Indian infants is necessary to determine country-specific
feasible and sustainable targets to further reduce morbid-
ity and mortality. Therefore, we used data from Six Week
Extended-Dose Nevirapine (SWEN), a recently com-
pleted NIH randomized clinical trial of prevention of
mother-to-child HIV transmission (PMTCT) among
breastfed infants in Pune, India [11] to investigate all-
cause hospitalization rates among HIV-infected and
HIV-exposed, uninfected infants. We also examined
cause-specific hospitalization rates, as well as hospitaliza-
tion reasons, and risk factors for hospitalization among
HIV-infected and HIV-exposed, uninfected infants. We
specifically sought to compare the impact of SWEN on
infant hospitalization rates as the PMTCT trial had ear-
lier shown reduced mortality rates among infants who
received SWEN compared to single-dose nevirapine
(sdNVP) and because SWEN has been incorporated into
the new WHO PMTCT guidelines [12]. We hypothesized
that respiratory-related hospitalizations would predomi-
nate throughout the first 12 months of life and the pro-
portion of gastrointestinal-related hospitalizations would
increase over the first 12 months of life.
Methods
Study Design
This is a secondary analysis of the infant outcomes col-
lected as part of the SWEN trial, which was conducted
from August 2002 to September 2007. Full details of the
parent study have been previously described [12]. In
brief, all infants received standard of care (sdNVP) at
birth and then were randomized to receive either the
daily study intervention of nevirapine plus multivitamins
from day 8 to 42 of life or multivitamins alone from day
8 to 42. Women with the intention to exclusively breast-
feed were enrolled and encouraged to rapidly wean after
the first four months of infant life, which was the local
standard of care during this study for women who did
not have access to safe, affordable, sustainable formula
feeding options [13]. Written consent was obtained
where possible; for eligible women who could not read,
consent was obtained orally and documented in writing
by a witness. Institutional Review Boards in Pune, India
and Baltimore, United States approved the study.
Study Population
Pregnant women, >18 years, were recruited from the
antenatal clinic, labor ward, or postpartum ward within
72-hours of delivery at Byramjee Jeejeebhoy Medical
College (BJMC)/Sassoon Hospital in Pune, India. All
randomized singleton and twin infants born to HIV-
infected women were included.
Study Follow-up
Infant study visits were scheduled at 1, 2, 3, 4, 5, 6, 10,
and 14 weeks, and 6, 9, and 12 months of life. Heel-
stick and venipuncture blood specimens were collected
for HIV testing within 48 hours of birth and at each fol-
low-up visit except weeks 3 and 5, until diagnosis was
confirmed. At each scheduled and illness visit, medical
history, physical exam, and laboratory studies were per-
formed. Infants were offered cotrimoxazole prophylaxis
at 4-6 weeks of life for primary prevention of Pneumo-
cystis jirovecii pneumonia (PCP). All infants were fol-
lowed for 12 months. No vaccines were given as part of
this study. Infants and their mothers received routine
pediatric health care from their own providers, including
any recommended vaccinations, which at the time of the
study did not include Hib, pneumococcal or rotavirus
vaccines. HAART was not available through the govern-
ment program during this study so only infants who
were HAART eligible and whose families could afford
to pay for HAART out-of-pocket received HAART.
Study Definitions and Analysis
The primary outcome of this study was all-cause 12-
month hospitalization rate among HIV-exposed infants.
Secondary outcomes included cause-specific 12-month
hospitalization and in-hospital mortality rates according
to HIV status, as well as reasons, and risk factors for
hospitalization.
Hospitalization and Mortality
Hospitalization was defined as any overnight admission
for any reason during the first 12 months of life. Three
cause-specific reasons for hospitalization were evaluated:
gastroenteritis, sepsis/meningitis, and pneumonia. WHO
guidelines for presumed or probable clinical diagnosis
were used by staff physicians [14]. All hospitalizations
were verified by the study team, including those at hos-
pitals other than the study site hospital. Hospitalization
event data were extracted from electronic medical
records of adverse events reported as part of the clinical
trial. Death was documented by a physician if it
occurred at the hospital or verbal autopsy if the death
occurred at home. In-hospital mortality was defined as
any death that occurred during hospitalization.
HIV Status
HIV status was categorized as infected if a positive DNA
PCR test was confirmed by an HIV-1 RNA PCR test
(>5,000 copies/ml) at a subsequent visit. All test results
underwent external quality assurance as described
elsewhere [12].
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Cotrimoxazole use was categorized based on adherence
to WHO guidelines [15]. Duration of any breastfeeding
was determined by the last visit date of ongoing breast-
feeding and was divided into 3 categories based on
WHO guidelines [16].
Maternal Variables
The maternal CD4 cell count, viral load, and hemoglo-
bin collected closest to delivery were used. Hemoglobin
categories were based on WHO guidelines[17]. Delivery
type was categorized as vaginal (spontaneous, breech, or
forceps assisted) or surgical (vacuum extraction, elective,
or emergent caesarian section). Maternal HAART use
included HAART prescribed during any point of the
study.
Statistical Analysis
Baseline characteristics of the infants and their mothers,
as well as, reasons for hospitalizations were summarized
using descriptive statistics. Means with standard devia-
tions were used for normally distributed data; medians
with interquartile range (IQR) were used for non-normal
distributions. For normally distributed data, the means
were compared using a Student’s t-test and for non-nor-
mal data, medians were compared with non-parametric
tests like Mann-Whitney. Proportions were compared
using chi-squared or Fisher’s exact test, whichever was
appropriate. Ninety-five percent confidence intervals
were used and two-sided p < 0.05 was considered
significant.
If infants were hospitalized multiple times, each hospi-
talization was counted separately in the rate calculations.
If an infant received multiple diagnoses during one hos-
pitalization, a single reason for hospitalization was
recorded according to the following order: meningitis/
sepsis > pneumonia > gastroenteritis > tuberculosis >
syphilis. Hospitalization recorded as sepsis included
those due to pneumonia, gastroenteritis, or other causes.
Risk rates were compared using Poisson regression.
Univariate Poisson regression analyses were performed
with infant and maternal predictors with all-cause hos-
pitalization. Selection of risk factors for multivariate
analysis, using Poisson regression, was based on biologi-
cal significance and statistical significance in the univari-
ate analysis. Data were analyzed using STATA version




A total of 737 infants contributed to 695 person-years
(PY) of follow-up; 93 (13%) infants were HIV-infected,
a n d1 5( 1 6 % )w e r eo nH A A R Tb y1 2m o n t h so fl i f e .
Although both groups were counseled the same, a
higher percentage of HIV-infected infants received cotri-
moxazole (66% vs. 38%, p < 0.001) and were breastfed
for a longer duration (171 vs. 101 days, p = 0.03) com-
pared to HIV-exposed, uninfected infants (Table 1).
Mothers of HIV-infected infants had lower median
maternal CD4 cell counts (366 vs. 494, p = 0.01) and
higher log viral loads (4.56 vs. 3.73, p < 0.001) closest to
t h et i m eo fd e l i v e r y ,w e r em o r el i k e l yt ob eo nH A A R T
(15% vs. 8%, p = 0.01) at any time during the study, and
had higher gravidity compared to mothers of HIV-
exposed, uninfected infants (Table 1).
Among the 737 infants, 260 (35%) were hospitalized at
least once for a total of 381 hospitalizations. Eighty (30%)
of these 260 were hospitalized multiple times (range 2-6).
HIV-infected infants were more likely to be hospitalized
once (47% vs. 34%, p < 0.05) and multiple times (20% vs.
9%, p < 0.05); however median duration of first hospitali-
zation (6 days vs. 7 days, p = 0.48) and annual days of
hospitalization (8 days vs. 6 days, p = 0.79) were similar
to that of HIV-uninfected infants. Sepsis/meningitis and
pneumonia-related hospitalization frequency increased
until 14 weeks of life, then decreased. Gastrointestinal-
related hospitalizations steadily increased over time,
peaking around 9 months (Figure 1). Other reasons for
hospitalization (non-infectious or infections other than
gastrointestinal, respiratory, sepsis/meningitis) were high-
est in the neonatal period and decreased thereafter.
Hospitalization Rates
The overall all-cause hospitalization rate was 548/1000
PY (95% CI: 495/1000 PY- 606/1000 PY). HIV-infected
infants were 1.82-fold more likely to be hospitalized for
any reason (906/1000 PY vs. 497/1000 PY, 95% CI: 1.40-
2.34) and were more likely to be hospitalized for each of
the cause-specific infections, particularly gastroenteritis
(229/1000 PY vs. 107/1000 PY, RR 2.14, 95% CI: 1.23-
3 . 5 8 )c o m p a r e dt oH I V - e x p o s e d ,u n i n f e c t e di n f a n t s
(Table 2). However, there were no statistically significant
differences in all-cause or cause-specific hospitalization
rates according to infants who received single dose ver-
sus six weeks of extended dose of nevirapine prophylaxis
(SWEN) (data not shown).
In-Hospital Mortality
Overall, 27 (4%) infants died during the 12-month fol-
low-up; 13/93 were HIV-infected infants and 14/644
were HIV-exposed, uninfected infants (14% vs. 2%, p <
0.05). Five (1.9%) of 260 hospitalized infants died in the
hospital during the 12-month follow-up; 3/44 hospita-
lized infants were HIV-infected and 2/216 were HIV-
exposed, uninfected (6.8% vs. 0.9%, p = 0.01). The med-
ian length of total hospitalization among infants who
died in the hospital was greater than those who did not
die in the hospital but this did not reach statistical
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of death among these 5 infants were gastroenteritis, sep-
sis, jaundice, and pneumonia. The overall and in-hospi-
tal mortality rates were 6.36-fold (152/1000 PY vs. 24/
1000 PY, 95% CI: 2.75-14.60) and 10.3-fold (35/1000 PY
vs. 3/1000 PY, 95% CI: 1.18-123.07) higher among HIV-
infected infants compared to HIV-exposed, uninfected
infants, respectively (Table 2).
Reasons for Hospitalization
Hospitalization was more often due to infectious mor-
bidity than non-infectious morbidity (56% vs. 44%)
(Table 3). Together - gastroenteritis, pneumonia and
sepsis/meningitis accounted for 63% of infectious hospi-
talizations and 36% of total hospitalizations. Among
hospitalized infants 5 had dual diagnoses of sepsis and
pneumonia and 5 had sepsis and gastroenteritis. Abnor-
mal laboratory values accounted for the majority of
non-infectious hospitalizations, particularly abnormal
bilirubin in the neonatal period.
Risk Factors for Hospitalization
In adjusted analysis, infant HIV infection, advanced
maternal age, and younger gestational age at birth
Table 1 Infant and maternal baseline characteristics among 737 HIV-exposed infants by infant HIV status at 12
months of life in Pune, India







Female gender, n (%) 737 46 (49) 301 (47) 0.62
Gestational age (weeks), median (IQR) 732 39 (38-40) 39 (38-40) 0.13
APGAR at 5 minutes, median (IQR) 737 8 (8-9) 8 (8-9) 0.48
Birth weight (grams), median (IQR) 732 2550 (2450-2950) 2650 (2400-3000) 0.29
WHO-guided Cotrimoxazole use 737 61 (66) 247 (38) <0.001
Any breastfeeding (days), median (IQR) 718 171 (98-276) 101 (98-182) 0.03
<4 months, n (%) 398 42 (45) 356 (57)
4 - 6 months, n (%) 75 6 (6) 69 (11) 0.02
>6 months, n (%) 264 45 (48) 219 (34)
Extended dose nevirapine, n (%) 737 41 (44) 326 (51) 0.24
Infant HAART, n (%)† 737 15 (16) n/a n/a
Maternal Characteristics
Age (years), median (IQR) 733 24 (21-26) 23 (21-25) 0.09
Gravidity, median (IQR) 619 2 (1-3) 2 (1-3) 0.01
Married, n (%) 733 90 (97) 624 (97) >0.99
Education 737
Primary (<6 years), n (%) 294 44 (48) 250 (39)
Secondary (6-10 years), n (%) 376 39 (42) 337 (52) 0.17
Tertiary (>10 years), n (%) 67 10 (12) 57 (9)
Hindu religion, n (%) 733 76 (82) 493 (77) 0.27
Vaginal delivery, n (%) 737 77 (83) 513 (80) 0.48
Hemoglobin* 737
Normal (>11 g/dl), n (%) 364 36 (38.7) 328 (50.9)
Mild Anemia (10-11 g/dl), n (%) 210 12 (12.9) 90 (14.0) 0.06
Moderate Anemia (7-10 g/dl), n (%) 140 35 (37.6) 188 (29.2)
Severe Anemia (<7 g/dl), n (%) 23 10 (10.8) 38 (5.9)
CD4 cell count (cells/mm
3),median (IQR)* 636 366 (217-549) 494 (334-682) 0.01
Viral load (Log 10) (copies/ml), mean (SD)* 682 4.56 (0.9) 3.73 (1.0) <0.001
Maternal HAART, n (%)† 737 14 (15) 48 (8) 0.01
Maternal AZT, n (%)
≠ 737 224 (35) 24 (26) 0.09
Maternal NVP, single-dose, n (%)
≠ 737 54 (58) 431 (67) 0.09
NOTES:
*Values closest to delivery are reported.
†HAART use during any time of the study.
‡ P-values based on chi-square, Fisher’s exact, Median test or un-paired t-test.
≠AZT = zidovudine for PMTCT, NVP = nevirapine (intrapartum, single-dose) for PMTCT.
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was protective (Table 4). There were too few pneumonia
and sepsis/meningitis-related hospitalization events to
adequately evaluate risk factors for these. Compared to
>6 months of any breastfeeding, shorter breastfeeding
duration of <4 or 4-6 months was associated with 2.44-
fold (95% CI: 1.29-4.64) and 2.39-fold (95% CI: 0.94-
6.10) increased risk of gastroenteritis-related hospitaliza-
tion, respectively (adjusted for infant HIV status, cotri-
moxazole use, and maternal AIDS)(data not shown).
Figure 1 Other reasons for hospitalization include infections, other than those specifically listed, as well as non-infectious reasons. The
full list of reasons is reported in Table 3.
Table 2 Hospitalization and mortality rates among 737 HIV-exposed infants at 12 months of life in Pune, India
Overall HIV-infected HIV-exposed, uninfected Rate Ratio
N = 737 N = 93 N = 644
cases Rate/1000 PY (95%
CI)
cases Rate/1000 PY (95%
CI)





All-cause 260 548 (495-606) 44 906 (717-1129) 216 497 (443-556) 1.82 (1.40-2.34) <0.001
Cause-specific
Gastroenteritis 65 122 (98-151) 16 229 (140-354) 49 107 (83-136) 2.14 (1.23-3.58) <0.05
Sepsis/
Meningitis
44 63 (46-85) 7 103 (47-196) 33 58 (40-80) 1.79 (0.76-3.80) 0.14
Pneumonia 23 35 (22-51) 5 57 (28-63) 18 31 (19-49) 1.83 (0.53-5.07) 0.25
Mortality
In-Hospital
† 5 7 (2-17) 3 35 (7-103) 2 3 (0.4-12) 10.3 (1.18-
123.07)
0.02
Overall 27 40 (27-59) 13 152 (81-261) 14 24 (13-40) 6.36 (2.75-14.60) <0.001
NOTES:
Case was defined as the number of infants experiencing the event. All-cause hospitalization includes any reason for hospitalization. The causes of death for the 5
infants who died in-hospital include sepsis, pneumonia (2), gastroenteritis, and jaundice.
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In this study, nearly 50% of HIV-infected Indian infants
were hospitalized by 12 months of life at almost twice
the hospitalization rate of HIV-exposed, uninfected
Indian infants. Infections were the predominant reason
for hospitalization, and gastroenteritis was the leading
infectious cause of infant hospitalization in our cohort,
which was counseled to exclusively breastfeed and
abruptly wean at four months of life (revised to six
months towards the end of the study). Sepsis/meningitis
and pneumonia-related hospitalizations accounted for
lower than expected proportion of hospitalizations, and
gastrointestinal-related hospitalizations appeared to peak
around 9 months of life. As expected, infant HIV status
was a significant predictor of hospitalization risk along
with prematurity and advanced maternal age. In-hospital
mortality was 10-fold higher among HIV-infected
infants compared to HIV-exposed, uninfected infants.
There are limited comparable hospitalization data
among HIV-infected infants in other resource-limited set-
tings. A South African study of HIV-infected children <5
years (67% <1 year) not on ART reported a hospitalization
frequency of 47.9% [19], nearly identical to our finding of
47%. Another similar South African study of HIV-infected
infants (birth-3 months) reported a lower hospitalization
frequency of 18% and a rate of 2.33/1000 PY [20]. These
comparisons are limited by age at outcome, breastfeeding
details, and cotrimoxazole prophylaxis. Among HIV-
exposed, uninfected infants not on ART, the following
hospitalization frequencies have been reported: 5% by 3
months of life in South Africa [20], 6% at 12 months of
life in Zambia [8], 17% at 6 months of life in Latin Amer-
ica [9], and 20.4% at 12 months among children <5 years
(67% <1 year) in South Africa [19]. Overall, our hospitali-
zation findings among HIV-infected infants appear similar
to those of South Africa, which bears the highest world-
wide burden of HIV infection. Some key differences in our
cohort was that approximately half of them were on a
short course antiretroviral prophylaxis regimen, majority
were breastfed and all were participants in a clinical trial;
however similar to the above-mentioned studies very few
of the HIV-infected infants received HAART. Therefore
some of these differences may make it difficult to make a
complete comparison across studies.
As with all-cause hospitalization, there are few data
available on cause-specific hospitalization. Furthermore,
the available data, particularly hospitalizations due to
infections, are limited by lack of pathogen specificity
and comparisons across studies are hampered by differ-
ent methods of ascertainment and duration of follow-
up. Among categories of infection, we found a higher
frequency of gastroenteritis-related hospitalization in
our cohort compared to that reported in sub-Saharan
African studies. A South African study of HIV-infected
infants (birth-3 months) reported 7.7% of gastroenteri-
tis-related hospitalization [20], compared to our 17% at
Table 3 List of reasons for 381 hospitalizations among 737 HIV-exposed infants at 12 months of life in Pune, India
N (%) N (%)
Infectious 215 (56.0) Non-infectious 166 (44.0)
Gastroenteritis 67 (17.6) Hyperbilirubinemia 35 (9.2)
Meningitis or sepsis 44 (11.5) Abnormal chemistry values† 32 (8.4)
Pneumonia 25 (6.6) Neutropenia 21 (5.5)
Rash without fever 19 (5.0) Anemia 12 (3.1)
Syphilis 18 (4.7) Prematurity, low birth weight, small for gestational age 12 (3.1)
Conjunctivitis 15 (3.9) Congenital anomaly 11 (2.9)
Impetigo 7 (1.8) Respiratory distress syndrome 11 (2.9)
Upper respiratory infection 7 (1.8) Meconium aspiration 8 (2.1)
Fever 5 (1.3) Seizure 6 (1.6)
Tuberculosis 5 (1.3) Failure to thrive 4 (1.0)
Cellulitis 3 (0.8) Thrombocytosis 2 (0.5)
Hepatitis 1 (0.3) Other skin conditions 2 (0.5)
Urinary tract infection 1 (0.3) Trauma/abuse 2 (0.5)
Skin abscess 1 (0.3) Irritability or colic 3 (0.8)
Bleeding 1 (0.3)
Umbilical granuloma 1 (0.3)
NOTES:
for infants with multiple diagnoses, infectious diseases were listed as the primary reason for hospitalization.
†Includes abnormal liver or renal function tests.
The 18 infants hospitalized for syphilis were admitted for treatment based on maternal syphilis serological diagnoses. The 15 infants hospitalized for
conjunctivitis and 7 for upper respiratory infection were admitted for symptoms assessment, respectively; no other diagnoses were reported at discharge. Among
hospitalized infants 5 had dual diagnoses of sepsis and pneumonia and 5 had sepsis and gastroenteritis.
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months of life in Pune, India
Univariate Multivariate
IRR 95% CI P-value IRR 95% CI P-value
Infant Characteristics
HIV status
HIV-infected 1.82 1.42-2.33 <0.001 1.52 1.14-2.02 <0.05
HIV-exposed, uninfected 1.00
Female gender 0.73 0.60-0.90 <0.05 0.73 0.59-0.91 <0.05
Gestational age
<37 weeks 1.93 1.48-2.52 <0.001 1.55 1.11-2.17 0.01
≥37 weeks 1.00
APGAR at 5 minutes 1.01 1.001-1.008 0.02 1.00 1.00-1.01 0.16
Birth weight
<2500 grams 1.35 1.09-1.67 <0.05 1.12 0.86-1.46 0.40
≥2500 grams 1.00
Breastfeeding duration
<4 months 1.04 0.83-1.29 0.75 1.06 0.85-1.34 0.60
4 - 6 months 0.98 0.69-1.41 0.93 1.01 0.70-1.47 0.94
>6 months 1.00
Cotrimoxazole use
WHO-guided 1.14 0.94-1.40 0.19 1.05 0.83-1.32 0.68
Non WHO-guided 1.00
Extended-dose nevirapine




Yes 2.20 1.37-3.53 <0.05
No 1.00
Maternal Characteristics
Age (years) 1.06 1.03-1.09 <0.001 1.04 1.00-1.07 0.03
Gravidity 1.11 1.00-1.22 0.04 1.04 0.93-1.16 0.49
Marital status
Not married 1.26 0.71-2.24 0.43
Married 1.00
Education
Primary (<6 years) 0.80 0.65-0.98 0.04 1.32 0.87-1.99 0.19
Secondary (6-10 years) 0.72 0.49-1.07 0.11 1.13 0.76-1.70 0.54
Tertiary (>10 years) 1.00
Religion
Hindu 1.05 0.82-1.35 0.68
Non-Hindu 1.00
Housewife
Yes 0.78 0.61-0.99 0.04 0.88 0.68-1.13 0.31
No 1.00
Delivery type




Severe (<7 g/dl) 2.66 1.74-4.05 <0.05 1.24 0.85-1.83 0.27
Moderate (7-<10 g/dl) 1.21 0.92-1.60 0.17 1.18 0.93-1.51 0.17
Mild (10-11 g/dl) 1.32 1.04-1.67 0.02 1.22 0.89-1.66 0.22
Normal (>11 g/dl) 1.00
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enteritis-related hospitalization [21] among HIV-
exposed, uninfected infants (3-9 months of life), com-
pared to our 7.6% at 12 months. One potential explana-
tion for higher rates of gastroenteritis-related
hospitalization in our cohort may be the common
Indian practice of mixed feeding and animal milk substi-
tutes for infant feeding, which we have previously
observed [22,23]. A limitation of our study however is
that the precise details of breastfeeding was not known
at the time of this publication, but mixed feeding and
milk substitutes also likely contributed to our high rates.
Abrupt weaning is also likely to be an important contri-
butor. Abrupt weaning in a large Zambian study was
associated with significantly increased risk of HIV infec-
tion and gastrointestinal illness [24]. Furthermore,
breastfeeding for shorter duration (<4 and <4-6 months)
was associated with an over 2.0-fold increased risk of
gastroenteritis-related hospitalization compared to >6
months. Similar results were found in Zambia where
breastfeeding for <5 months among HIV-infected infants
were associated with increased mortality compared to
longer breastfeeding [24]. Because of such data [21,24]
abrupt breastfeeding cessation is no longer recom-
mended by the WHO and exclusive breastfeeding for at
least 6 months is recommended to protect infants
against excessive morbiditya n dm o r t a l i t yw h e ni n f a n t
formula is not affordable, feasible, acceptable, sustain-
able or safe [25]. The low rates of pneumonia-related
hospitalization could be related to relatively high rates
of cotrimoxazole use, even if not strictly according to
WHO guidelines.
Our observed in-hospital mortality rates (with 16% of
infants on ART) were lower than what has been
observed in studies from sub-Saharan Africa (among
infants not on ART). In South Africa, 13.2% [26] and
16.5% (children <5 years with 67% <1 year) [19] HIV-
infected infants died in-hospital compared to our
observed 6.8%. Similarly, higher proportions of in-hospi-
tal mortality have been reported among South African
HIV-exposed, uninfected infants- 5.2% [26] and 4.6%
(children <5 years with 67% <1 year) [19] compared to
0.9% seen in our study. The remaining 22 of 27 deaths
occurred outside the hospital. Most of these occurred in
the home, presumably with infants succumbing to ill-
n e s s e sb e f o r eb e i n ga b l et ob eb r o u g h tt ot h eh o s p i t a l
for care.
The lower overall and in-hospital mortality seen in
our study may be explained by the increased availability
of health care services provided in a clinical trial setting,
as none of the comparative studies were part of a clini-
cal trial. In addition, many of our hospitalizations in the
non-infection category occurred in response to abnor-
mal laboratory values, some of which were likely trig-
gered because of the increased monitoring that occurred
within a clinical trial. Nonetheless, the frequency of in-
hospital death among both HIV-infected and HIV-
exposed, uninfected infant groups highlights the need
for aggressive management of hospitalized infants and
the importance of preventive measures.
Table 4 Risk factors for all-cause hospitalization using Poisson regression among 737 HIV-exposed infants at 12




3) 1.93 1.40-2.67 <0.05 1.17 0.82-1.68 0.39
≥200 (cells/mm
3) 1.00
Viral load (Log 10)
¥
≥5 log (copies/ml) 1.38 1.09-1.74 <0.05 1.15 0.89-1.47 0.28
<5 log (copies/ml) 1.00
Maternal HAART
†
Yes 1.55 1.15-2.09 <0.05 1.31 0.94-1.83 0.11
No 1.00
Maternal AZT*
Yes 0.86 0.69 - 1.07 0.17
No 1.00
Maternal NVP*
Yes 0.66 0.54-0.81 <0.05 0.85 0.68-1.07 0.16
No 1.00
NOTES:
†HAART use among HIV-infected mothers or infants at any time during the study. Infant HAART use was not included in the multivariate model as it was only
applicable to HIV-infected infants.
¥Reported values are closed to delivery.
*AZT = zidovudine for PMTCT, NVP = nevirapine (intrapartum, single-dose) for PMTCT.
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Page 8 of 10Consistent with known predictors of infant morbidity,
older maternal age, infant HIV infection, and prematur-
ity predicted all-cause hospitalization. Interestingly,
female gender was protective of all-cause hospitalization,
which is consistent with reports of greater female infant
immunity against infection and lower mortality from
infections than among male infants in all income set-
tings [27]. In contrast to other studies, we did not iden-
tify maternal CD4, viral load, or HAART use to be risk
factors for infant hospitalization. This is possibly
explained by differential health parameters, such as the
low percentage of mothers with AIDS in India (7% in
this study) compared to African studies (20-30%).
Although extended nevirapine has previously been
shown to reduce mortality in HIV-exposed breastfed
infants [12], we found little data to suggest that it was
mediated through a reduction in hospitalization or in-
hospital mortality rates.
This study had several limitations. Since it analyzed a
secondary endpoint of the parent study, the ability to
detect statistical differences among secondary endpoints
according to HIV status was limited. Little microbiological
data were available to support most infectious diagnoses
in this study, but WHO-guided probable and presumed
diagnoses were used to standardize morbidity defini-
tions [14]. Our data were generated in the context of a
clinical trial setting and therefore may have underesti-
mated the rate of infant hospitalization in the community
as follow-up was frequent and many tertiary care services
were readily available. Lastly, infant vaccination records
(other than BCG given at birth) were not routinely col-
lected in this study, and may have had an impact on fre-
quency and distribution of hospitalization morbidity.
However, despite these limitations, the data were carefully
collected at several time points within the context of a
clinical trial and provide among the best longitudinal data
on hospitalization rates from HIV-exposed Indian infants.
Consclusions
In conclusion, HIV-exposed Indian infants, especially
HIV-infected Indian infants, experienced a high burden
of hospitalization morbidity and mortality. Infections
accounted for over half the hospitalizations with gastro-
enteritis being the most common cause among this
HIV-exposed infant population. It is therefore critical to
scale-up HIV PMTCT programs and enhance imple-
mentation of effective vaccinations, cotrimoxazole pro-
phylaxis, prenatal care, and safe infant feeding practices
which have all been shown to reduce infectious morbid-
ity and all-cause mortality among HIV-exposed, infants.
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